Roche to acquire US firm Poseida Therapeutics in $1.5 billion deal
ZURICH (Reuters) -Switzerland's Roche will acquire U.S. biopharma firm Poseida Therapeutics in a cash deal worth up to $1.5 billion, ...
Read moreDetailsZURICH (Reuters) -Switzerland's Roche will acquire U.S. biopharma firm Poseida Therapeutics in a cash deal worth up to $1.5 billion, ...
Read moreDetails
